Home Blog Page 186

Discover Taiwan’s Wangye Culture: 2026 Kunshen Wangye’s Salt for Peace Festival Invites the World to Celebrate “Peace Without Borders”

By
Advertorial Desk
-
TAINAN, TAIWAN – Media OutReach Newswire – 7 September 2026 – The 2026 Kunshen Wangye’s Salt for Peace Festival, one of Taiwan’s major celebrations of Wangye folk religion, will take place on November 7 and 8 at Nankunshen Daitian Temple in Beimen District, Tainan, co-organized by the Southwest Coast National Scenic Area Headquarters and local partners.

Under this year’s theme, “Salt Sustains Peace, Happiness Follows,” the festival will introduce the concept of “Peace Without Borders” for the first time, bringing together Wangye religious traditions, salt industry heritage, wetland ecology, and international cultural exchange. Travelers from around the world are invited to visit Tainan and experience Taiwan’s distinctive religious culture and coastal scenery.

The festival will continue the three traditional rituals of “Inviting the Salt,” “Blessing the Salt,” and “Giving Thanks for the Salt,” symbolizing peace, health, and happiness. This year, a Korean traditional blessing group will also participate in a cultural exchange for the first time, sharing wishes for peace through different cultural traditions. A “Wall of Blessings from Around the World” will also be set up at the venue, with bilingual blessing cards available for visitors from around the world to write down their wishes, allowing messages of peace and well-being to transcend languages and borders.

The festival will also feature international arts performances, specialty markets, family activities, bilingual guided tours, and the distribution of blessed salt sachets. In addition to participating in the festivities, visitors can explore the Jingzaijiao Tile-Paved Salt Fields and discover Beimen’s distinctive blend of religious heritage, salt-making culture, and coastal ecology.

More than a celebration of religious culture, the 2026 Kunshen Wangye’s Salt for Peace Festival serves as a platform connecting culture, tourism, and international exchange. Travelers from around the world are warmly invited to visit Beimen, Tainan, on November 7 and 8 to experience the heartfelt wishes embodied in “Peace Without Borders” and discover the unique cultural appeal of Taiwan.

Hashtag: #TaiwanWangyeCulture

The issuer is solely responsible for the content of this announcement.

New Vientiane-Udon Thani Bus Route to Launch on 9 September

By
Thongsavanh Souvannasane
-
This photo is used for representational purpose only.

Thailand has just announced the launch of a new bus route connecting Laos’ Vientiane and Thailand’s Udon Thani International Airport, via Udon Thani city, strengthening cross-border travel links between the two countries.

The Thai Transport Company (BKS), Thailand’s state-owned intercity and cross-border bus operator, will begin operating the service on 9 September.

The 87-kilometer route will use a 40-seat, second-class air-conditioned bus, with fares set at THB 80 (USD 2.40) per trip. Two round trips will operate each day.

Buses will depart Udon Thani Bus Terminal 1 at 9 AM., stop at Udon Thani International Airport at 9:30 AM., and arrive in Vientiane at noon.

The return service will leave Vientiane at 2 PM, reach Udon Thani Airport at 4:30 PM., and arrive at Udon Thani Bus Terminal 1 at 5:00 PM.

The route will provide a direct bus connection between Udon Thani and Vientiane, including stops at the airport in Udon Thani.

The launch builds on BKS’s recent resumption of another major cross-border route linking Vientiane and Khon Kaen, a neighboring province of Udon Thani.

In October 2025, BKS relaunched the Khon Kaen route after a five-year suspension that began in March 2020 due to the COVID-19 pandemic.

The Khon Kaen route covers 194 kilometers and takes approximately four hours, using air-conditioned buses that seat 42 passengers. BKS charges 180 baht (around USD 5) per ticket and runs two daily round trips, departing Khon Kaen at 8:15 AM and returning from Vientiane at 2:45 PM.

Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

By
Advertorial Desk
-

HONG KONG, Sept. 7, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that, the ordinary shares of the Company (the “Shares”), which trade on The Stock Exchange of Hong Kong Limited (the “HK Stock Exchange”), have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect (collectively, the “Hong Kong Stock Connect”) programs, both with effect from September 7, 2026, pursuant to the announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, recently. Following the inclusion of the Shares, eligible investors in Chinese Mainland will be able to trade the Shares through the Hong Kong Stock Connect channel.

The Company believes the inclusion of the Shares in the trading mechanism of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect demonstrates market recognition of the Company’s investment value and growth prospects. The Company expects the inclusion of the Shares as eligible securities will help further expand the shareholder base of the Company, increase the trading liquidity of the Shares, and support the innovation-driven and sustainable growth of the Company in the long term.

About the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are mutual stock market access mechanisms between Chinese Mainland and the Hong Kong Special Administrative Region, under which the Shanghai Stock Exchange and the Shenzhen Stock Exchange have established technical connectivity with the HK Stock Exchange, respectively, to enable investors in Chinese Mainland and the Hong Kong Special Administrative Region to trade eligible securities listed on each other’s market through their local securities companies or brokers.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once monthly subcutaneously and once daily orally, and ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

Laos Warns of More Rain, Flash Floods, Landslides in Early September

By
Soutthida Sinbandith
-
Laos to Experience Chilly, Rainy Weather Throughout This Week
Rain falling on roof in Laos (photo: tarm nun)

Laos will see more rain this week, with the Department of Meteorology and Hydrology warning of possible flash floods, landslides and urban flooding in vulnerable areas.

On 7 September, the department said the low-pressure trough will continue moving across central Laos, while the southwest monsoon remains active over most of the country. The conditions are expected to bring thunderstorms and scattered rain, with moderate to heavy rain and strong winds possible in parts of central and southern Laos.

In Vientiane, rain is expected in parts of the capital, including Pak Ngum, Sangthong, Xaythany, Sikhottabong, Sisattanak, Xaysettha and Naxaithong. Temperatures are forecast to reach around 34°C.

Rain is also expected in Vientiane Province, including Phonhong and Vang Vieng, as well as parts of Xaysomboun and Borikhamxay provinces.

The department warned that moderate rain could cause waterlogging in poorly drained areas. Heavy rain could trigger flash floods, landslides and rapidly rising water levels in streams, while rainfall above 90 millimeters could bring a higher risk of severe flooding and landslides.

Residents in vulnerable areas have been urged to monitor weather updates and official warnings, particularly during periods of prolonged rain.

Vientiane Checks Drainage Systems

Vientiane authorities are also preparing for further heavy rain.

Deputy Minister of Agriculture and Environment Saynakhone Inthavong inspected drainage systems and waterways in Xaythany and Sikhottabong districts on 4 September.

The inspection covered natural drainage channels in Vankham Village and the Huay Xay Moun Dam and drainage pump in Nong Da Village.

Saynakhone ordered authorities to urgently repair damaged water pumps, particularly those affected by damaged power lines, and ensure drainage systems are ready to operate during heavy rain.

Officials were also instructed to strengthen monitoring and planning to prevent water from reaching homes and agricultural areas.

Authorities in Sekong Province are also assessing damage from recent disasters in Kalum District.

Officials reported damage to roads and 9.7 hectares of productive land, including rice fields, upland farms and orchards.

On 5 September, district authorities donated LAK 40 million (USD 1,800) toward bridge repairs, along with supplies and school materials for affected communities.

The latest warning comes as several parts of Laos continue to recover from flooding and landslides caused by heavy rain in recent weeks.

Air Quality

Meanwhile, monsoon rains continue to shape weather conditions and air quality across Laos. In Vientiane Capital and the central region, air quality remains generally good, with average PM2.5 levels at around 8.2 μg/m³, within World Health Organization guidelines.

Air quality may occasionally reach AQI levels of 21 to 49 due to vehicle emissions and urban construction activity.

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

By
Advertorial Desk
-

— Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection —

— Robust neutralizing antibody responses across RSV, hMPV and PIV3 in Phase 2 recapitulates Phase 1 results demonstrating best-in-class breadth (with no immune interference) and no drop-off in responses in the oldest participants (75+ years) —

— Favorable safety & tolerability profile and successful 2,000L commercial-scale production further de-risk late-stage development and commercialization —

SHANGHAI, Sept. 7, 2026 /PRNewswire/ — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary data from a Phase 2 clinical trial in older adults in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover’s validated Trimer-Tag vaccine technology platform.

“We are pleased to announce positive Phase 2 clinical data strengthening the potential first-in-class and best-in-class profile for our RSV+hMPV±PIV3 combination vaccine candidates, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection,” said Joshua Liang, Chief Executive Officer & Board Director of Clover. “The positive Phase 2 results significantly de-risk future late-stage development. Importantly, the results also continue to validate our differentiated Trimer-Tag platform for the development of multi-valent protein-based respiratory vaccines that have the potential to make an impact on public health and on chronic diseases caused by respiratory viruses[1].” 

The ongoing Phase 2 trial for Clover’s combination vaccine candidates is a randomized, observer-blinded, multi-center study with 420 older adults (60-85 years) enrolled in Australia, and the participants have been randomized to receive either SCB-1022 (RSV + hMPV), SCB-1033 (RSV + hMPV + PIV3) or placebo.

Immunogenicity

  • Antibody titers (geometric mean titers [GMTs]) at 28 days post-vaccination in the Phase 2 were generally in-line with or trended higher than the prior Phase 1 trial.
  • Geometric mean fold rises (GMFRs) in neutralizing antibodies (nAbs) at 28 days post-vaccination compared to pre-vaccination:
    • RSV nAbs: Approximately 6-9 fold increases
    • hMPV nAbs: Approximately 6-8 fold increases
    • PIV3 nAbs: Greater than 3 fold increase (approximately 5 fold increase in participants with baseline PIV3 nAbs in the bottom tertile), driven by up to approximately 20 fold increases in PIV3 PreF-specific antibodies[2]
  • No drop-off in antibody responses observed in the oldest participants (75+ years) compared to younger participants (60-74 years).
  • No signs of immune interference on RSV and hMPV nAbs from the addition of PIV3 PreF antigen in SCB-1033 (RSV+hMPV+PIV3) compared to SCB-1022 (RSV+hMPV).

Respiratory Tract Infections (Based on AE Reporting)

  • Approximately 62% lower rate of respiratory tract infection was observed in the vaccine groups (SCB-1022 and SCB-1033) versus the placebo group within 28 days of vaccination based on AE reporting of any respiratory tract infections (no PCR sequencing of infection cases was conducted in the study).
  • Significant RSV outbreak[3] with co-circulation[4] of hMPV and PIV in Australia occurred during the study enrollment and follow-up period.

Safety and Reactogenicity

  • SCB-1022 and SCB-1033 were generally well-tolerated; solicited local and systemic adverse events (AEs) within 7 days of vaccination were mostly mild and all transient.
    • The most common solicited AEs were fatigue, headache and injection site pain, with mean durations of approximately 2 days for the vaccine groups (SCB-1022 and SCB-1033) and the placebo group. 
  • The frequency of unsolicited AEs within 28 days of vaccination was similar across the vaccine and placebo groups.
  • There were no vaccine-related serious adverse events (SAEs), AEs of special interest (AESIs), or AEs leading to discontinuation.

Commercial-Scale Manufacturing Scale-Up

  • In parallel with the Phase 2 trial, Clover conducted commercial-scale 2,000L bioreactor scale-up production of multiple batches of Trimer-Tagged RSV, hMPV and PIV3 PreF antigen components of SCB-1022/1033.
  • The successful 2,000L production process scale-up further de-risk future late-stage development and commercialization.

Based on these positive Phase 2 results for the RSV + hMPV ± PIV3 combination vaccine candidates further validating the Trimer-Tag platform, Clover will continue to evaluate continued mid- and late-stage development plans as well as potential global collaboration opportunities for value maximization.   

About Clover 

Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.   

Clover Forward-looking Statements  

This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “going forward,” “intend,” “may,” “might,” “ought to,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.   Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time.

[1] RSV and/or influenza vaccines have been demonstrated to reduce worsening of COPD, Asthma, cardiovascular disease (CVD) and chronic liver disease (CLD). Sources: (A) DOI: 10.1016/j.chest.2026.06.059 (CHEST Study), (B) DOI: 10.1002/14651858.CD002733.pub3, (C) DOI: 10.3389/fphar.2025.1701127, (D) DOI: 10.1136/bmjopen-2018-031070.
[2] PIV3 PreF-specific nAbs (such as Site Ø and Site X) can potently neutralize the PIV3 virus (DOI: 10.1038/s41467-023-36459-3) , but unlike RSV and hMPV, the majority of pre-existing PIV3 nAbs at baseline are against the PIV3 HN protein (whereas levels of pre-existing PIV3 nAbs against the PIV3 PreF protein at baseline are low) (DOI: 10.1038/s41564-024-01722-w). Therefore, a numerically lower increase in total PIV3 nAbs induced by SCB-1033 (containing PIV3 PreF antigen) – as compared to increases in RSV and hMPV nAbs – is expected.
[3] Australia Immunisation Coalition (Aus. Gov. Department of Health, National Notifiable Diseases Surveillance System). Jan-May 2026.
[4] Australia CDC. % of severe ARI (acute respiratory infection) cases sent to a sentinel intensive care. Jan-May 2026.

 

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

By
Advertorial Desk
-

SHANGHAI, Sept. 7, 2026 /PRNewswire/ — Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management’s unwavering confidence in the company’s intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group’s long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns.

In the first half of 2026, Fosun Pharma’s earnings quality continued to improve, with revenue contributions from innovative drugs and international markets steadily increasing. Core operational indicators further consolidated upon the foundation of 2025:

  • Revenue: RMB 20,442 million, up 4.75% year-on-year;
  • Profit attributable to shareholders of the listed company, net of non-recurring gains and losses: RMB 1,144 million, up 19.09% year-on-year;
  • Net cash generated from operating activities: RMB 2,424 million, up 13.59% year-on-year.

The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, with total consideration of around US$294 million. Upon completion of the transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma’s financial statements. Net proceeds from the transaction will primarily be allocated toward the Company’s R&D investments, share repurchases, and the repayment of interest-bearing debts. As the controlling shareholder, Fosun Pharma remains fully confident in Gland Pharma’s long-term development and its enduring role as a key engine for overseas value creation.

Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates. This repurchase program is intended to convey the Company’s confidence in its intrinsic value and to generate sustainable returns for shareholders.

VITG Unveils Modern Managed Services and Managed Detection & Response as Part of a Broader AI and Cybersecurity Transformation across ANZ

By
Advertorial Desk
-

SYDNEY, Sept. 7, 2026 /PRNewswire/ — As organisations across Australia and New Zealand navigate the accelerating impact of artificial intelligence, increasingly sophisticated cyber threats, and growing governance requirements, Virtual IT Group   (VITG) has announced the launch of Modern Managed Services  (MMS)  and Managed Detection & Response  (MDR) , that are next-generation managed services and managed security offerings designed to help organisations remain secure, resilient and ready for what’s next.

Virtual IT Group (VITG): Jeremy Nees, CPO, Maurice McCarthy, CEO and Sash Vasilevski, CSO
Virtual IT Group (VITG): Jeremy Nees, CPO, Maurice McCarthy, CEO and Sash Vasilevski, CSO

Modern Managed Services delivers a Modern Defensible Architecture framework for managed IT operations, ensuring security controls, governance frameworks and operational best practices are embedded and continuously maintained. Complementing this, Managed Detection & Response provides organisations with 24×7 Security Operations Centre (SOC) capability, actively monitoring, investigating and responding to threats using advanced security analytics and response technologies.

Jeremy Nees , Chief Product Officer, VITG , said:

“Too often, organisations purchase managed services only to discover they do not have the standard level of security they need. As businesses adopt AI, the old-world IT solutions that Managed Service Providers (MSP) are selling are simply not going to cut it. We’ve baked common security requirements into the MMS service from day one, applying the key principles of Modern Defensible Architecture: Secure-by-Design, Defense in Depth, and Zero Trust.

MDR and ZDR   can be layered on top or are available independently if you have your own IT service or team. The push to adopt AI is leaving security gaps across the ANZ mid-market. Our goal is to provide customers with technology that is secure, resilient, and ready for what’s next.”

The launch marks VITG’s second major solution release of the year, following the introduction of its Zero Trust Consulting Practice  and Zero Trust Detection & Response  (ZDR)  offering earlier in 2026. It is also the Group’s first launch since acquiring cybersecurity outfit Security Centric , building on the addition of Auckland based The Instillery  in 2025 and further strengthening VITG’s capabilities across managed services, cloud, cybersecurity, data and AI. VITG is also advancing a dedicated Data & AI Practice and Momentum, a continuous improvement framework currently being piloted with customers ahead of a market launch later this year.

Since joining VITG  at the start of the year, Maurice McCarthy , Chief Executive Officer , is committed to moving at pace to meet the demand that has been created off the back of the market’s rapid adoption of AI.   

McCarthy said, “The traditional managed services model was built for a different era. Today’s organisations need partners that can help them unlock the value of data and AI while strengthening cybersecurity, managing risk, and continuously evolving their technology environment.

Through the acquisition of Security Centric and The Instillery we have brought together market-leading expertise across managed services, data and AI, and cybersecurity. This launch is the first of several innovations we will introduce as we help organisations accelerate transformation and realise greater value from AI.”

Sash Vasilevski , Chief Security Officer, VITG , said:

“The technology businesses are using to unlock the value of AI, integrate systems, and build strong data foundations, is rapidly introducing new risks and attack surfaces.

As business leaders accelerate their adoption of AI, the gap between the threats they face and the security capabilities they have in place is growing faster than many businesses realise.”

Modern Managed Services and Managed Detection & Response are available immediately.

For more information, visit:

Modern Managed Services (MMS)

Managed Detection & Response (MDR)

NANO Nuclear Energy and Enveniam Sign Memorandum of Understanding to Advance U.S. Nuclear Fuel Cycle, Microreactor Deployment and Energy Infrastructure

By
Advertorial Desk
-

Collaboration Framework Encompasses Nuclear Fuel Transportation, Conversion and Deconversion, Microreactor Licensing and Deployment, Advanced Manufacturing, and Power Solutions for Data Centers and Remote Communities

New York, New York and Oak Ridge, Tennessee – Newsfile Corp. – September 4, 2026 – NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced that it has signed a non-binding Memorandum of Understanding (“MOU”) with Enveniam, LLC (“Enveniam”), a leading project integrator and provider of engineering, technology and project-delivery solutions, to explore a collaboration addressing nuclear fuel cycle infrastructure, microreactor commercialization, advanced manufacturing and end-user energy solutions.

Figure 1 – NANO Nuclear Energy and Enveniam Sign Memorandum of Understanding to Advance U.S. Nuclear Fuel Cycle, Microreactor Deployment and Energy Infrastructure

To view an enhanced version of this graphic, please visit:
https://laotiantimes.com/wp-content/uploads/2026/09/312953_7732e902b4852b3b_003full.jpg

The MOU establishes a framework through which the companies will explore utilizing Enveniam’s experience in nuclear engineering, project integration, safety analysis, licensing support, project controls, operational readiness and complex energy infrastructure to advance NANO Nuclear’s developing reactor, nuclear fuel fabrication and transportation capabilities. Any specific services, funding, projects or commercial commitments between the parties would be subject to separate definitive agreements.

“This MOU brings together two organizations with complementary capabilities across the advanced nuclear value chain,” said Jay Yu, Founder and Chairman of NANO Nuclear Energy. “NANO Nuclear is building a vertically integrated platform spanning microreactors, nuclear fuel and transportation, while Enveniam brings extensive experience integrating complex nuclear and energy programs. By exploring opportunities together, we aim to strengthen the practical pathway from technology development to regulatory licensing, manufacturing and deployment, while preserving the flexibility to evaluate each potential project on its individual merits.”

“Enveniam is focused on bringing disciplined project integration, technical depth and delivery certainty to critical energy missions,” said Doug Freund, President and Chief Executive Officer of Boston Government Services and Executive Officer of Enveniam. “NANO Nuclear is advancing a broad portfolio that touches several important parts of the emerging advanced nuclear market. This framework gives our teams the opportunity to assess where Enveniam’s engineering, project controls, licensing, safety and operational capabilities can help translate promising nuclear technologies and infrastructure concepts into executable projects.”

Exploring Broad Cooperation Across the Nuclear Value Chain

Under the MOU, NANO Nuclear and Enveniam expect to evaluate potential cooperation across six principal workstreams:

  • Nuclear fuel transportation: engineering, safety, operational and regulatory support for NANO Nuclear’s HALEU transportation systems, including transport-basket optimization, regulatory filings and security protocols.
  • Conversion and deconversion: engineering design, criticality-safety analysis, integrated safety assessments and licensing-strategy support for potential uranium conversion and deconversion facilities.
  • Microreactor commercialization: technical support for siting, licensing, engineering, fabrication, project controls, risk management, safety-basis development, operations planning and deployment readiness for NANO Nuclear’s lead KRONOS MMR™ Energy System project or NANO Nuclear’s portable microreactor designs.
  • Advanced manufacturing: requirements development, project management, engineering design, baseline planning, earned-value management and operational-readiness support for a potential U.S.-based manufacturing facility for nuclear fuel, fuel components and microreactor modules.
  • Domestic fuel supply chain: strategic, program-management, technical and compliance support spanning sourcing, fabrication, qualification, transportation and delivery.
  • Commercial energy markets: joint market development and stakeholder engagement concerning potential electricity and process-heat solutions for data centers, remote and off-grid communities, Alaska Native organizations, island states and territories, and other energy-intensive users.

“Commercializing advanced nuclear technology requires more than a strong reactor design,” said James Walker, Chief Executive Officer of NANO Nuclear Energy. “It requires disciplined licensing, safety analysis, project controls, supply-chain coordination, manufacturing planning and operational readiness. Enveniam’s capabilities closely align with our expertise and business plans across these critical workflows. We believe this collaboration can help us evaluate projects more efficiently, identify execution risks earlier and build stronger delivery plans as opportunities advance toward definitive agreements.”

Building a Disciplined Path to Definitive Projects

The MOU calls for establishing a joint working group that would meet periodically to review potential business opportunities, identify projects that may warrant a funded statement of work or task order, and consider joint applications for federal or state funding. Each company would retain discretion over the information it shares and the opportunities it elects to pursue.

The MOU does not obligate either company to proceed with a particular project, provide services, commit funding or enter into a commercial transaction. Any such activity would require separate definitive agreements establishing the applicable scope, schedule, responsibilities, economics, intellectual-property arrangements and regulatory requirements.

Supporting Data Centers and Remote Communities

One area of potential collaboration is the development of reliable electricity and process-heat solutions for data centers and other energy-intensive customers. The rapid expansion of artificial intelligence, cloud computing, advanced manufacturing and electrification is increasing demand for safe, dependable, around-the-clock power and creating opportunities for advanced nuclear technologies that can complement and support existing grids and energy infrastructure.

NANO Nuclear and Enveniam also intend to evaluate opportunities involving remote and off-grid communities, including Alaska Native organizations and island jurisdictions that may rely heavily on imported fossil fuels. Potential applications could include resilient power, district or industrial heat, desalination and hybrid energy systems combining microreactors with renewable generation. Any deployment would remain subject to technical feasibility, stakeholder support, financing, licensing and definitive project documentation.

Strengthening the Domestic Nuclear Fuel Cycle

The MOU also supports NANO Nuclear’s broader strategy of developing capabilities across critical portions of the domestic nuclear fuel cycle. Through its subsidiaries Advanced Fuel Transportation Inc. and HALEU Energy Fuel Inc., NANO Nuclear is pursuing transportation and fuel-fabrication capabilities intended to support its own reactor programs and the wider advanced nuclear industry.

Enveniam’s experience in project integration, nuclear operations, engineering, safety, licensing, supply-chain management and operational readiness may complement NANO Nuclear’s work in fuel transportation, conversion and deconversion, fabrication and manufacturing. The companies believe that coordinated planning across these activities could help identify bottlenecks, improve project definition and support a more secure and resilient U.S. nuclear fuel supply chain.

About Enveniam
Enveniam, a Bernhard Capital Partners (BCP) portfolio company consisting of Boston Government Services (BGS), Strategic Management Solutions LLC (SMSI), and Sterling Engineering & Consulting (SE&C), advances the nation’s focus on energy dominance and national security through engineering, technology, and deep domain expertise. As a Lead Project Integrator, the company delivers integrated solutions across federal and energy markets, including nuclear, oil, natural gas, renewables and critical infrastructure. Enveniam brings the scale, agility and depth needed to address complex energy and security challenges.

About NANO Nuclear Energy, Inc.
NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, “ZEUS”, a portable solid core battery reactor, and the space focused, portable LOKI MMR™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

For more corporate information, please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:
Email: IR@NANONuclearEnergy.com
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward-Looking Statements
This news release and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events that may impact our expected future business and financial performance and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “aim,” “goal,” “explore,” “seek,” “believe,” “potential,” “will,” “should,” “could,” “would” or “may” or derivations of these words and other words of similar meaning about the future, although forward-looking statements may be denoted by other terms. In this press release, forward-looking statements include, without limitation, statements concerning the anticipated benefits to NANO Nuclear of the MOU with Enveniam and the parties’ goals of identifying areas of collaboration and entering into definitive agreements; and NANO Nuclear’s development, regulatory, manufacturing and commercialization plans generally. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors that may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause actual future results to differ materially from those expressed in our forward-looking statements include, but are not limited to: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S. nuclear licensing submissions; (ii) risks related to the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology; (iii) our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan; (iv) uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology within the timelines we anticipate, if ever; (v) the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including those of the DOE and NRC and those associated with the ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation; and (vi) similar risks and uncertainties associated with operating a developing business in a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use cash on hand faster or in different ways than anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

The issuer is solely responsible for the content of this announcement.

1...185186187...6,678Page 186 of 6,678